+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Argininosuccinic Aciduria - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 118 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294478
The argininosuccinic aciduria market size is expected to increase from USD 156.60 million in 2026 to USD 162.15 million in 2027 and reach USD 192.95 million by 2032, growing at a CAGR of 3.54% over 2027-2032. This report is Segmented by Disease Onset (Early-Onset and Late-Onset), Diagnosis Pathway (Newborn-Screening, and More), Treatment Modality (Dietary Protein Restriction, and More), Product (Glycerol Phenylbutyrate Oral Liquid, and More), End User (Metabolic Disease Centers, and More), Route of Administration (Oral, and More), and Geography (North America, and More). Forecasts in Value (USD).

Global Argininosuccinic Aciduria Market Trends and Insights

Expansion of Newborn Screening and Earlier Case Finding

Newborn screening serves as a key driver of patient identification in the argininosuccinic aciduria market. In 2024, Norway expanded its newborn screening program to include distal urea cycle defects, including argininosuccinic aciduria (ASA), increasing the total number of screened congenital diseases to 39. A 2025 Chinese study of 101 patients with urea cycle disorders found that newborn screening identified 57% of cases. Patients identified through screening received a diagnosis within the first month of life, while those diagnosed following symptom onset received diagnoses significantly later. In a separate Chinese cohort of patients with ASL deficiency, late-onset patients identified through newborn screening had a median age at diagnosis of 3 months, compared with 3.5 years for patients identified after symptom onset. Earlier diagnosis enables timely implementation of dietary management, supplementation, and nitrogen-scavenger therapy. As diagnostic programs expand, healthcare systems must ensure the availability of reliable confirmatory testing and timely access to treatment.

Transition From Brand-Only Nitrogen Scavenging to Multisource Supply

Multisource supply is reshaping the treatment economics of the argininosuccinic aciduria market. Endo launched the first U.S. generic version of Ravicti, glycerol phenylbutyrate oral liquid, in October 2025. Lupin received U.S. Food and Drug Administration approval for glycerol phenylbutyrate oral liquid in May 2026. Lupin reported that the reference product generated annual sales of USD 337 million for the year ended December 2025. The entry of additional suppliers can improve patient access where insurance coverage restricts the use of branded products. However, it may also erode branded-product revenue and increase payer emphasis on generic substitution. Zevra reported USD 0.8 million in OLPRUVA revenue for full-year 2025 and subsequently reduced its commercial investment, underscoring the challenges of driving product uptake without clear clinical differentiation.

Ultra-Rare Patient Pool Limits Commercial Trial Economics

The limited patient pool presents significant challenges to development economics in the argininosuccinic aciduria market. Available evidence estimates U.S. incidence at 1 in 218,750 births, restricting the number of patients eligible for disease-specific clinical studies. This limited population prolongs patient recruitment timelines and constrains the ability to recover development costs through treatment volumes. As a result, sponsors may pursue programs that address multiple urea cycle disorders, including ASA. For instance, Korro’s KRRO-121 targets hyperammonemia across urea cycle disorder genotypes rather than ASA alone. Zevra’s anticipated USD 0.8 million in OLPRUVA revenue in 2025 further underscores the difficulty of achieving commercial scale within a small treated population.

Other drivers and restraints analyzed in the detailed report include:

  1. ASL-Targeted RNA, Exosome, Gene-Editing, and Gene-Transfer Research
  2. Persistent Neurocognitive and Liver Disease Creates Demand Beyond Ammonia Control
  3. Diagnostic Heterogeneity and Underdiagnosis Obscure Treatable Demand

Segment Analysis

Early-onset ASA is projected to account for 55.4% of disease-onset revenue in 2026. The need for rapid intervention in this patient group, driven by the risk of neurological deterioration from neonatal hyperammonemia, supports sustained treatment demand. Patients typically initiate dietary management, arginine supplementation, and nitrogen-scavenger therapy shortly after diagnosis. This requirement for continuous treatment establishes a durable demand base in the argininosuccinic aciduria market. In the 2025 Chinese ASL-deficiency cohort, 70% of early-onset patients presented with liver dysfunction, reinforcing the need for follow-up care beyond acute ammonia reduction.

The late-onset ASA segment is forecast to grow at a CAGR of 5.6% through 2032. This segment includes adolescents and adults who may remain undiagnosed until molecular testing or symptom-based evaluation occurs. In the Chinese cohort, late-onset patients who did not undergo newborn screening had a median diagnosis age of 13 years, compared with 3 months among newborn-screened late-onset patients. In addition to nitrogen control, late-onset management may require neurological monitoring and liver surveillance. As diagnosis increasingly occurs beyond the neonatal period, the argininosuccinic aciduria market requires care pathways that address the long-term needs of these patients.

Newborn screening-identified cases are expected to generate 60.5% of diagnosis-pathway revenue in 2026. Screening reduces the time from birth to diagnosis and facilitates earlier referral of infants to specialist care. In 2024, Norway added distal urea cycle defects, including ASA, to its national screening panel, increasing the program's coverage to 39 congenital diseases. In China, a study of 101 patients with urea cycle disorders reported that newborn screening identified 57% of cases. As screening programs continue to expand, they are expected to establish a more consistent referral flow into the argininosuccinic aciduria market.

Molecularly confirmed cases are forecast to grow at a CAGR of 5.8% through 2032. Molecular confirmation supports the identification of patients with atypical presentations that may not be detected through initial screening profiles, particularly those with mild biochemical abnormalities or later-onset symptoms. The Chinese ASL-deficiency study found that normal ammonia levels during newborn screening did not prevent symptom development in some late-onset patients. Molecular testing also enables providers to differentiate ASL deficiency from other causes of neurological or hepatic symptoms. Symptom-diagnosed cases will remain relevant in regions with limited newborn screening coverage. Accordingly, the argininosuccinic aciduria market will continue to depend on both screening and clinical evaluation pathways.

Complete Report Scope:

  • By Disease Onset
    • Early-Onset Argininosuccinic Aciduria
    • Late-Onset Argininosuccinic Aciduria
  • By Diagnosis Pathway
    • Newborn-Screening-Identified Cases
    • Symptom-Diagnosed Cases
    • Molecularly Confirmed Cases
  • By Treatment Modality
    • Dietary Protein Restriction and Medical Nutrition
    • Arginine and Citrulline Supplementation
    • Nitrogen Scavengers
    • Acute Hyperammonemia Rescue
    • Liver Transplantation-Linked Care
  • By Product
    • Glycerol Phenylbutyrate Oral Liquid
    • Sodium Phenylbutyrate Tablets and Powder
    • Sodium Benzoate and Combination Rescue Products
    • Disease-Specific Medical Foods and Formula
  • By End User
    • Metabolic Disease Centers
    • Tertiary Hospitals
    • Specialty Pharmacies and Home Care
    • Other End Users
  • By Route of Administration
    • Oral
    • Enteral Tube
    • Intravenous
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Rest of the World

Geography Analysis

North America accounted for 42.7% of the argininosuccinic aciduria market share in 2026, maintaining the largest regional position. The region benefits from well-established specialist metabolic care networks, orphan-drug reimbursement frameworks, and high per-patient treatment expenditure. Lupin reported annual sales of USD 337 million for the reference glycerol phenylbutyrate product for the year ended December 2025. Endo launched the first generic glycerol phenylbutyrate liquid in the United States in October 2025, while Lupin’s approval in May 2026 introduced an additional generic alternative. This evolving mix of branded and generic products is expected to keep market access and pricing under close payer scrutiny.

Asia-Pacific is forecast to grow at a CAGR of 4.7% through 2032. Japan represents a key access market, following Ravicti’s national health insurance listing and launch in April 2026. The listed price was JPY 41,455.4 per unit. China is strengthening its diagnostic capacity through regional newborn screening programs. A 2025 study in Xinjiang reported expanded screening of 107,741 neonates between 2019 and 2024 using tandem mass spectrometry. This infrastructure can enhance the identification of inherited metabolic disorders and support earlier intervention. Although Asia-Pacific remains smaller than North America, continued investments in screening and patient access programs underpin its stronger growth outlook.

The Rest of the World remains an early-stage region within the argininosuccinic aciduria market. Immedica received approvals for Ravicti in the United Arab Emirates and Oman in March 2026, following earlier Gulf Cooperation Council approvals in Saudi Arabia, Kuwait, and Qatar. This phased regulatory expansion illustrates how regional licensing strategies can broaden rare-disease access across multiple markets. In Latin America and Sub-Saharan Africa, inconsistent newborn screening may delay diagnosis and restrict regular access to therapy. Available evidence identifies underdiagnosis as a key market barrier in regions where screening infrastructure and specialist care capabilities remain uneven.



Asia-Pacific is forecast to grow at a CAGR of 4.7% through 2032. Japan represents a key access market, following Ravicti’s national health insurance listing and launch in April 2026. The listed price was JPY 41,455.4 per unit. China is strengthening its diagnostic capacity through regional newborn screening programs. A 2025 study in Xinjiang reported expanded screening of 107,741 neonates between 2019 and 2024 using tandem mass spectrometry.

The Rest of the World remains an early-stage region within the argininosuccinic aciduria market. Immedica received approvals for Ravicti in the United Arab Emirates and Oman in March 2026, following earlier Gulf Cooperation Council approvals in Saudi Arabia, Kuwait, and Qatar. This phased regulatory expansion illustrates how regional licensing strategies can broaden rare-disease access across multiple markets. In Latin America and Sub-Saharan Africa, inconsistent newborn screening may delay diagnosis and restrict regular access to therapy. Available evidence identifies underdiagnosis as a key market barrier in regions where screening infrastructure and specialist care capabilities remain uneven.

List of Companies Covered in this Report:

  1. Acer Therapeutics Inc.
  2. Amgen
  3. Arcturus Therapeutics Holdings Inc.
  4. BioNTech
  5. Endo, Inc.
  6. Evox Therapeutics Ltd.
  7. Genevant Sciences Corporation
  8. Hongkong WinHealth Pharma Group Co. Ltd.
  9. Immedica Pharma AB
  10. Lucane Pharma SA
  11. Medunik USA
  12. Nestlé S.A.
  13. Orphan Pacific, Inc.
  14. Recordati S.p.A.
  15. Relief Therapeutics Holding SA
  16. Selecta Biosciences, Inc.
  17. Swedish Orphan Biovitrum AB (publ)
  18. Takeda Pharmaceuticals
  19. Ultragenyx Pharmaceutical Inc.
  20. Vitaflo International Ltd.
  21. Zevra Therapeutics, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expansion of Newborn Screening and Earlier Case Finding
4.2.2 Greater Use of Molecular Confirmation After Abnormal Citrulline Screens
4.2.3 Transition From Brand-Only Nitrogen Scavenging to Multisource Supply
4.2.4 Regional Rare-Disease Access Expansion Through Specialty Distributors
4.2.5 Persistent Neurocognitive and Liver Disease Creates Demand Beyond Ammonia Control
4.2.6 ASL-Targeted RNA, Exosome, Gene-Editing, and Gene-Transfer Research
4.3 Market Restraints
4.3.1 Ultra-Rare Patient Pool Limits Commercial Trial Economics
4.3.2 Lifelong Dietary and Multimodal Management Dilutes Drug-Only Revenue
4.3.3 Diagnostic Heterogeneity and Underdiagnosis Obscure Treatable Demand
4.3.4 Durability, Redosing, and Extrahepatic Disease Barriers for Genetic Therapies
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Disease Onset
5.1.1 Early-Onset Argininosuccinic Aciduria
5.1.2 Late-Onset Argininosuccinic Aciduria
5.2 By Diagnosis Pathway
5.2.1 Newborn-Screening-Identified Cases
5.2.2 Symptom-Diagnosed Cases
5.2.3 Molecularly Confirmed Cases
5.3 By Treatment Modality
5.3.1 Dietary Protein Restriction and Medical Nutrition
5.3.2 Arginine and Citrulline Supplementation
5.3.3 Nitrogen Scavengers
5.3.4 Acute Hyperammonemia Rescue
5.3.5 Liver Transplantation-Linked Care
5.4 By Product
5.4.1 Glycerol Phenylbutyrate Oral Liquid
5.4.2 Sodium Phenylbutyrate Tablets and Powder
5.4.3 Sodium Benzoate and Combination Rescue Products
5.4.4 Disease-Specific Medical Foods and Formula
5.5 By End User
5.5.1 Metabolic Disease Centers
5.5.2 Tertiary Hospitals
5.5.3 Specialty Pharmacies and Home Care
5.5.4 Other End Users
5.6 By Route of Administration
5.6.1 Oral
5.6.2 Enteral Tube
5.6.3 Intravenous
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Rest of the World
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 Acer Therapeutics Inc.
6.3.2 Amgen Inc.
6.3.3 Arcturus Therapeutics Holdings Inc.
6.3.4 BioNTech SE
6.3.5 Endo, Inc.
6.3.6 Evox Therapeutics Ltd.
6.3.7 Genevant Sciences Corporation
6.3.8 Hongkong WinHealth Pharma Group Co. Ltd.
6.3.9 Immedica Pharma AB
6.3.10 Lucane Pharma SA
6.3.11 Medunik USA Inc.
6.3.12 Nestlé S.A.
6.3.13 Orphan Pacific, Inc.
6.3.14 Recordati S.p.A.
6.3.15 Relief Therapeutics Holding SA
6.3.16 Selecta Biosciences, Inc.
6.3.17 Swedish Orphan Biovitrum AB (publ)
6.3.18 Takeda Pharmaceutical Company Limited
6.3.19 Ultragenyx Pharmaceutical Inc.
6.3.20 Vitaflo International Ltd.
6.3.21 Zevra Therapeutics, Inc.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acer Therapeutics Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Endo, Inc.
  • Evox Therapeutics Ltd.
  • Genevant Sciences Corporation
  • Hongkong WinHealth Pharma Group Co. Ltd.
  • Immedica Pharma AB
  • Lucane Pharma SA
  • Medunik USA Inc.
  • Nestlé S.A.
  • Orphan Pacific, Inc.
  • Recordati S.p.A.
  • Relief Therapeutics Holding SA
  • Selecta Biosciences, Inc.
  • Swedish Orphan Biovitrum AB (publ)
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Vitaflo International Ltd.
  • Zevra Therapeutics, Inc.